🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congratulations to Toni Choueiri, MD on being the recipient of a Doctorate Honoris Causa from The Lebanese University recognizing his outstanding achievements in Oncology.

🚨 Our new study alert! Elsevier What is the role of comorbidity burden in response to immunotherapy based combos in patients with metastatic renal cell carcinoma? 🎯Endpoints : Overall surival and time to treatment failure High comorbidity 🟰 Worse Outcomes ❓❗️No

Thursday is #WorldKidneyCancerDay! Stay tuned for posts throughout the day, and remember to register for the Global Patient & Carer Symposium: worldkidneycancerday.org #WKCD2025

Important, practice-informing study, from Dana-Farber Lank Center for Genitourinary Oncology IMDC Daniel Heng led by our star researcher Emre Yekedüz Ankara Üniversitesi in Clinical GU Cancer: clinical-genitourinary-cancer.com/article/S1558-…

🏆 The Yvonne Awards 2025 by OncoDaily Dario Trapani | Dr. Catharine Young | Bishal Gyawali, MD, PhD, FASCO | Darya Kizub, MD 🇺🇦 | Stella Kyriakides | Daniel Heng | Jasmine Kamboj, MD, FASCO | Marta Salek | Paolo Tarantino The Yvonne Awards 2025, presented by OncoDaily, took place on May 30th during ASCO 2025 in Chicago, set

Congrats to our all⭐️ faculty for #BOAV25 for breaking down the key #ASCO25 takeaways with a 🇨🇦 West lens 🙏 OncologyEducation BC Cancer Jonathan Loree Daniel Heng Maryam Soleimani MD

Risk stratification using the IMDC score

Last week Dr. Andy Wang 🇺🇦 & I published 1st of our translational research in #MolecularCancer BMC, developing a multifunctional immunotherapy nanoparticle (MINP) to treat #kidneycancer. Thanks to #KinmanAu & #SiqingLi, 2 of our postdocs UTSW Simmons Cancer Center who did the work. 1/n

Go Daniel Heng!

17/ Next, we use IMDC Daniel Heng to interrogate the clinical outcomes (TTF, OS, ORR) of patients with metastatic ChRCC vs. ccRCC, across various 1L regimens: -Significantly poorer outcomes with 1L ICI-based regimens in ChRCC vs. ccRCC -Similar outcomes with 1L VEGF-TT

Bravo Chris Labaki Eddy Saad both now BIDMC IM Residency for a landmark paper about Chromophobe Kidney Cancer. A tumor that remain a mystery in biology, but less so after this work. Wonderful mentorship from David Braun Eli Van Allen Sachet Ashok Shukla Lisa Henske ! CC: Yale Cancer Center

1/ Recently, our lab has worked with outstanding groups (#TeamScience) to address some key questions in kidney cancer immunobiology: Can we use machine-learning approaches to classify RCC and predict response? Cancer Cell What drives exceptional response with immunotherapies?

Gem/cis/durvalumab is approved in the EU for muscle invasive bladder cancer (NIAGARA study). It’s the only immune therapy study in the adjuvant or neoadjuvant setting with significant OS. ⬆️ pCR and EFS support this appr OncoAlert Annals of Oncology astrazeneca.com/media-centre/p…

News From Industry Source: AstraZeneca The European Commission has approved AstraZeneca’s Imfinzi (durvalumab) as the first and only perioperative immunotherapy for resectable muscle-invasive #BladderCancer (MIBC), based on results from the Phase III NIAGARA trial. In

The 4th live Uromigos meeting is happening on 7th & 8th Nov ‘25 in Nashville. It’s going to have an international flavour with America’s 🇺🇸 🇨🇦 vs Eurasia 🇯🇵 🇨🇳 🇮🇳 🇦🇺 🇪🇺 Uromigos Cup competition (details to follow). Sessions ranging from ADCs in MIBC to the changing shape of

Chromophobe renal cell carcinoma is difficult to treat - Research in Journal of Clinical Oncology provides better understanding of this rare kidney cancer, potential treatment pathways & immunotherapy strategies. Dana-Farber Lank Center for Genitourinary Oncology Eddy Saad Chris Labaki BIDMC ➡️ bit.ly/3IhLT8d

Longer follow up for Enfortumab Vedotin & Pembro in urothelial cancer Annals of Oncology shows mOS at nearly 3 yrs (34 mnths) with 50% of responses (68%) continuing at 2 years! Experience in tox management is important. Duration of therapy uncertain in CR gbr01.safelinks.protection.outlook.com/?url=https%3A%…

Please check out our editorial just out in Nature Reviews Urology on a pragmatic approach to biomarkers for RCC! Many challenges, but with now some emerging promising biomarkers! ari hakimi Ed Reznik Robert Motzer MD Memorial Sloan Kettering Cancer Center MSK Department of Medicine nature.com/articles/s4158…

📢🗣️ New trial analysis from #FASTRACKII: in kidney cancer, SABR ⬆️ efficacy and ⬇️ cost than radiofrequency or cryoablation #kcsm #radonc 🔹 QALYs: SABR 4.00 vs RFA/CA 3.07 🔹 Cost: SABR A$31,053 vs RFA A$35,001 vs CA A$36,356 🔹 Net savings ~$4K/patient shorturl.at/b7ZOb

Register now: 2025 FDA-AACr-SITC workshop: approach to novel oncology endpoint development. Sep 11, 2025 inperson or virtual. aacr.org/professionals/…